Veru targets Phase 3 enobosarm trials following promising Phase 2b results in obesity treatment
Q1 2025 Management View Veru highlighted its transformation into a late clinical-stage biopharmaceutical company focusing on cardiometabolic and inflammatory diseases, with major developments in ...